The new drug "Bemeijing", jointly developed by Jiangsu Wangao Pharmaceutical and Beijing Merson Pharmaceutical, was approved for marketing by the National Medical Products Administration (NMPA) on Sept 30. 

Based in Haimen, Jiangsu, Wangao Pharmaceutical is a pharmaceutical enterprise committed to R&D, production, and sales of chemical drugs and traditional Chinese medicine. 

This product represents the world's first approved topical gel formulation designed for the treatment of proliferative superficial infantile hemangiomas. Infantile hemangiomas are the most prevalent benign tumors encountered during infancy, with a global incidence rate estimated to range between 5 percent and 12 percent. Superficial hemangiomas constitute nearly 70 percent of all cases. As a locally applied topical treatment drug designed for infants, the launch of Bemeijing provides a safe, effective, and convenient new treatment choice for pediatric patients. 

With comprehensive development in innovative drugs, improved new medications, and high-end generics, the company's products cover multiple therapeutic areas, including cardiovascular diseases, diabetic complications, and anti-tumor treatments. 

Jiangsu Wangao Pharmaceutical Co in Haimen district, Nantong. [Photo/WeChat account: haimenfabu] 

The automatic production line of the Jiangsu Wangao Pharmaceutical Co. [Photo/WeChat account: haimenfabu] ‌